Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
10 août 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
04 août 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Dyne...
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
12 juil. 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical and Regulatory Strategy: Clinical Trial...
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
05 juil. 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) --...
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
03 juin 2022 07h30 HE
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown
16 mai 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) --...
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
02 mai 2022 16h05 HE
|
Dyne Therapeutics, Inc.
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 - WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Dyne...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
10 mars 2022 07h30 HE
|
Dyne Therapeutics, Inc.
- Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 -- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and...
Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors
03 mars 2022 07h30 HE
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
18 janv. 2022 08h00 HE
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...